Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 10/21 10:46:08 am
74.6 CHF   -0.80%
10/20 NOVARTIS : The American Heart Association and Novartis Shine a Light..
10/20 Positive Phase III Clinical Trial Results for Ribociclib (LEE011)..
10/20 CERULEAN PHARMA : CERU) Files An 8-K
News SummaryMost relevantAll newsSector news 

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

share with twitter share with LinkedIn share with facebook
share via e-mail
05/14/2012 | 06:55pm CEST

--FDA concludes safety review of MS drug Gilenya

--FDA advises against use in certain heart and stroke patients

--FDA says no clear link between Gilenya and cardiovascular deaths

(Updates with additional background on EMA review starting in seventh paragraph and information on experimental Biogen Idec MS drug.)

   By Jennifer Corbett Dooren 

The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug.

The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug.

The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily.

As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear."

The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines.

Europe's drug regulator, the European Medicines Agency, last month requested stronger safety warnings for Gilenya after the agency concluded its review of the drug.

Gilenya is currently the only oral MS drug on the market but its sales prospects have been clouded by recent safety concerns. It was approved in the U.S. in 2010 and has been available in Europe since 2011.

The product is designed to treat patients with the relapsing form of MS, which is a progressive disease that involves damage to the nerves controlling muscles and vision.

The FDA is currently reviewing another oral MS drug from Biogen Idec Inc. (BIIB) called BG-12 that is designed to work through a different mechanism than Gilenya. Biogen Idec last week announced that the FDA accepted BG-12's new drug application for a standard 10-month review, which sets an agency decision deadline of about Dec. 28.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
10/20 NOVARTIS : Researchers Submit Patent Application, "2'-Branched Nucleosides for T..
10/20 NOVARTIS : breakthrough therapy LEE011 ribociclib plus letrozole demonstrates su..
10/20 NOVARTIS : The American Heart Association and Novartis Shine a Light on America'..
10/20 Positive Phase III Clinical Trial Results for Ribociclib (LEE011), an Investi..
10/19 CERULEAN PHARMA : CERU) Higher on $20M Purchase Agreement with Aspire Capital, A..
10/19 NOVARTIS : Kala azar the bane of West Pokot  
10/18 NOVARTIS : Alcon launches the CyPass Micro-Stent at the American Academy of Opht..
10/18 Pfizer to start shipping biosimilar version of J&J's Remicade in November
10/17 NOVARTIS : Alcon launches the CyPass® Micro-Stent at the American Academy of Oph..
More news
Sector news : Pharmaceuticals - NEC
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJPFIZER : J&J Brushes Off Pfizer's Challenge -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/20 Collaborative Leukemia Trial Orbits Moonshot Initiative
10/19 Pfizer Takes Risk For Biosimilar Followers
10/19 Cerulean inks collaboration with Novartis and nabs $20M equity investment at ..
10/17 Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2016 Update
10/14 Therapy Focus - Curis Thinks Small To Hit Big Immuno-Oncology Target
Financials ($)
Sales 2016 48 959 M
EBIT 2016 11 644 M
Net income 2016 7 920 M
Debt 2016 14 564 M
Yield 2016 3,75%
P/E ratio 2016 22,35
P/E ratio 2017 20,47
EV / Sales 2016 4,38x
EV / Sales 2017 4,26x
Capitalization 199 797 M
More Financials
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 89,1 $
Spread / Average Target 18%
Consensus details
EPS Revisions
More Estimates Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-13.71%199 797
JOHNSON & JOHNSON11.83%314 270
ROCHE HOLDING LTD.-15.41%202 648
PFIZER INC.0.81%197 376
MERCK & CO., INC.17.23%171 222
More Results